Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytarabine + daunorubicin (Jazz Pharmaceuticals plc)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CPX-351 (Vyxeos) is a liposomal formulation of the antineoplastic agents cytarabine and daunorubicin, encapsulated at a fixed 5:1 molar ratio. This specific ratio was identified in vitro to maximize synergistic antileukemic activity. The liposomal delivery system (approximately 100 nm in diameter) protects the drugs from rapid metabolism and excretion, providing a prolonged plasma half-life and preferential accumulation within the bone marrow, where the liposomes are internalized by leukemia cells. CPX-351 is FDA-approved for the treatment of adults and pediatric patients (1 year and older) with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). It is also being investigated for efficacy in patients with myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) who have failed hypomethylating agent therapy.
- Brand names
- Vyxeos
- Other names
- liposomal cytarabine and daunorubicincytarabine-daunorubicin liposome
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on cytarabine + daunorubicin (Jazz Pharmaceuticals plc).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytarabine + daunorubicin (Jazz Pharmaceuticals plc).